BiotechTube
Home/Pipeline/Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)

Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)

Rheumatoid Arthritis

Pre-clinicalDevelopment (Partnership)

Key Facts

Indication
Rheumatoid Arthritis
Phase
Pre-clinical
Status
Development (Partnership)
Company
LFB

About LFB

The LFB Group is a leading French biopharmaceutical laboratory dedicated to providing healthcare professionals with critical medicinal products derived from plasma or recombinant proteins. Operating with a strong public health mission, it serves as an essential link between plasma donors and patients, developing and manufacturing biomedicines for serious, chronic, and rare diseases. With nearly 3,100 employees worldwide and sales of €599.6 million in 2024, LFB is a key player in ensuring therapeutic sovereignty in France while expanding its international footprint across Europe, the Americas, and other global markets.

View full company profile

Therapeutic Areas

ImmunologyHaemostasisIntensive Care

Other Rheumatoid Arthritis Drugs

DrugCompanyPhase
Early Detection Test for Rheumatoid ArthritisAge LabsDevelopment
Piclidenoson (CF101)Can Fite BiopharmaPhase II/III
ERNA-201Eterna TherapeuticsPreclinical
Tc99m TilmanoceptNavidea BiopharmaceuticalsPhase 2/3
Monoclonal Antibody Biosimilar (Anti‑TNF)USV Biologics DivisionPhase 1
EYD-001 (Takinib analog)EydisBioPreclinical
LFD-200Lifordi ImmunotherapeuticsPhase 1
MEV-N01MesenbioPre-clinical
CIT-013CitryllPhase 2a
Restem-LRestemPhase 2
ASIT PlatformAhead TherapeuticsPre-clinical
AX-158Artax BiopharmaPhase 2